US 12,303,558 B2
Cancer prevention and therapy by inhibiting soluble tumor necrosis factor
Nikola L. Vujanovic, Pittsburgh, PA (US); and Lazar Vujanovic, Pittsburgh, PA (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed on Mar. 10, 2023, as Appl. No. 18/182,211.
Application 18/182,211 is a continuation of application No. 16/688,930, filed on Nov. 19, 2019, granted, now 11,633,464.
Application 16/688,930 is a continuation of application No. 15/776,061, granted, now 10,543,264, issued on Jan. 28, 2020, previously published as PCT/US2016/066552, filed on Feb. 14, 2016.
Claims priority of provisional application 62/269,839, filed on Dec. 18, 2015.
Prior Publication US 2023/0285526 A1, Sep. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 31/00 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/525 (2006.01); G01N 33/53 (2006.01); A61K 45/06 (2006.01)
CPC A61K 39/001117 (2018.08) [A61K 38/2013 (2013.01); A61K 38/2046 (2013.01); A61K 38/2086 (2013.01); A61K 39/001139 (2018.08); A61K 39/00114 (2018.08); A61P 35/00 (2018.01); C07K 14/525 (2013.01); A61K 2039/57 (2013.01); A61K 45/06 (2013.01)] 10 Claims
 
1. A method for inhibiting the development of, or treating a tumor in a subject, comprising administering to a subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-α protein and/or nucleic acid encoding the DN-TNF-α protein in combination with an antibody, thereby inhibiting the development of the tumor in the subject.